News

Er-Kim and CNX Therapeutics Forge Groundbreaking Partnership

Er-Kim and CNX Therapeutics Forge Groundbreaking Partnership

Groundbreaking Partnership Announcement

Er-Kim, an international pharmaceutical enterprise known for its expertise in novel therapies, has announced a significant partnership with CNX Therapeutics. This exclusive agreement focuses on distributing a selection of oncology products across Central and Eastern Europe (CEE) and Türkiye, marking a pivotal step for both companies.

Exclusive Distribution Agreement

The agreement positions Er-Kim as the exclusive distributor of CNX Therapeutics' oncology medication portfolio, which includes established products like Cardioxane and Savene. These treatments are set to enhance the oncology landscape across CEE, ensuring that patients have better access to essential therapies.

The Role of Er-Kim in Oncology

With over 40 years of experience in the pharmaceutical industry, Er-Kim has built a reputation as a trusted provider of oncology treatments within the region. Mert Zorlular, President & CFO of Er-Kim, expressed enthusiasm for this collaboration, highlighting the commitment to improving the quality of life for cancer patients through effective therapeutic solutions.

Strengthening Global Reach

This partnership not only enhances the portfolio available to healthcare providers but also allows CNX Therapeutics to tap into Er-Kim's well-established distribution network in Central and Eastern Europe. According to Pete Butterfield, Chief Operating Officer at CNX Therapeutics, the collaboration is a strategic move to broaden their market access and meet the needs of patients more effectively.

About Er-Kim

Founded in 1981, Er-Kim leads in biopharmaceutical innovation and commercialization. Partnered with over 40 global pharmaceutical leaders, Er-Kim's portfolio includes more than 68 products distributed across over 50 countries, showing their commitment to overcoming international healthcare challenges. The company boasts a dedicated workforce of over 300 professionals and impressive annual revenues exceeding EUR 305 million.

About CNX Therapeutics

CNX Therapeutics is committed to improving patient lives through access to essential medications. This specialty pharmaceutical company focuses on a range of therapeutic areas across over 60 markets worldwide. Their portfolio includes solutions for neurological, psychiatric, and critical care scenarios, positioning them as a key player in the global pharmaceutical landscape.

Contact Information

For media inquiries regarding this significant partnership, please contact:

Rosalia Scampoli
Marketcom PR
Tel: (914) 815-1465
Email: rscampoli@marketcompr.com

Mehdi Juma
CNX Communications Manager
Email: mehdi.juma@cnx-therapeutics.com

Frequently Asked Questions

What is the nature of the partnership between Er-Kim and CNX Therapeutics?

Er-Kim and CNX Therapeutics have entered into an exclusive agreement to distribute oncology products across Central and Eastern Europe and Türkiye.

What products will be included in this distribution agreement?

The agreement includes oncology medications such as Cardioxane and Savene from CNX Therapeutics' established portfolio.

When was Er-Kim founded?

Er-Kim was established in 1981 and has become a leader in biopharmaceutical innovation.

How many professionals does Er-Kim employ?

Er-Kim has a dedicated team of over 300 professionals working globally.

What is CNX Therapeutics' focus area?

CNX Therapeutics specializes in providing essential medicines for neurological, psychiatric, and critical care, with a commitment to ethical standards and sustainability.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 245

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 477

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 20

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 42

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 317

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 214

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 572

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

Old National Bancorp Declares Dividends to Benefit Shareholders

Updated Category News Views 180

Old National Bancorp Declares Cash Dividends Old National Bancorp, the holding company of Old National Bank, has recently made an important announcement regarding its quarterly dividends. The Board of Directors has officially declared a cash dividend of $0.14 per share on the Company’s outstanding shares of common stock. This move underlines the company’s commitment...

Continue Reading
Revolutionary Portable Target Board Streamlines Axe Throwing Fun

Updated Category News Views 295

Innovative Design for Axe Throwing Enthusiasts A new invention is transforming the world of axe throwing. A creative inventor sought to develop a robust solution for supporting heavy wooden targets. With this ambition in mind, he has introduced the AXXMAN BOARD, which enhances the experience of axe throwing while also ensuring safety and stability. This product aims to...

Continue Reading
AI Innovations Transforming Automotive Lighting Market Growth

Updated Category News Views 158

AI Innovations Transforming Automotive Lighting Market Growth The global automotive lighting market is poised for remarkable growth, with an expected increase of approximately USD 12.38 billion between 2024 and 2028. This growth is largely driven by the rising demand for advanced interior lighting systems, particularly in passenger and commercial vehicles. The advent of...

Continue Reading
Wolverine World Wide Insider Purchase Signals Optimism

Updated Category News Views 148

Wolverine World Wide Insider Purchase Signals Optimism In a recent filing, it has come to light that DeMonty Price, a board member of Wolverine World Wide (NYSE:WWW), made a significant insider purchase, affirming confidence in the future of the company. Details of the Transaction On a recent date, Price purchased 25,000 shares of Wolverine World Wide. This strategic move...

Continue Reading
Saigon Technology's Impact on Vietnam's Global Innovation Scene

Updated Category News Views 205

Saigon Technology's Impact on Vietnam's Global Innovation Scene Saigon Technology is making waves in the tech world, showcasing Vietnam's potential as a vibrant hub for global innovation. This remarkable company has recently achieved significant milestones that solidify its position in the industry. With its unyielding commitment to excellence, Saigon Technology has...

Continue Reading